Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism

Area of Science:

• Immunology
• Neuroscience
• Pharmacology

Background:

• Tyrphostin AG126 (AG126) is a protein tyrosine kinase (PTK) inhibitor with demonstrated benefits in inflammatory disease models.
• The precise molecular targets and cellular mechanisms of AG126's anti-inflammatory effects have remained largely unknown.

Purpose of the Study:

• To elucidate the molecular targets and mechanisms underlying the therapeutic effects of AG126 in experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis.
• To investigate the dual mechanism of action involving Bruton's tyrosine kinase (BTK) and a malononitrile (MN)-sensitive pathway.

Main Methods:

• Treatment of EAE model mice with AG126.
• Assessment of clinical symptoms, Th17 cell differentiation, central nervous system (CNS) inflammation, microglia activation, and myelin damage.
• In vitro assays to investigate AG126's direct inhibition of BTK and its hydrolysis products, including malononitrile (MN).

Main Results:

• AG126 significantly alleviated EAE clinical symptoms, reduced Th17 differentiation, decreased CNS inflammation and microglia activation, and attenuated myelin damage.
• AG126 was shown to directly inhibit Bruton's tyrosine kinase (BTK).
• AG126 hydrolysis yielded malononitrile (MN), which contributed to some anti-inflammatory effects, particularly on Toll-like receptor (TLR)-induced cytokine expression in microglia, but intact AG126 was required for full EAE protection.

Conclusions:

• AG126 exerts anti-inflammatory effects in EAE through a dual mechanism involving direct BTK inhibition and a novel MN-sensitive pathway.
• The interplay between BTK inhibition and MN-mediated effects, particularly on TLR signaling, highlights a complex therapeutic strategy.
• These findings suggest that targeting both BTK and the MN-sensitive pathway holds significant therapeutic potential for managing immune dysfunctions in autoimmune and inflammatory diseases.